| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Steven J Isakoff | |
| P2860 | cites work | Molecular portraits of human breast tumours | Q28032461 |
| Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer | Q28372484 | ||
| Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer | Q29614302 | ||
| Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer | Q33304691 | ||
| High-dose cis-diamminedichloro-platinum therapy in patients with advanced breast cancer: pharmacokinetics, toxicity, and therapeutic efficacy | Q33485091 | ||
| Sites of distant recurrence and clinical outcomes in patients with metastatic triple-negative breast cancer: high incidence of central nervous system metastases | Q33715354 | ||
| The platinum agents: a role in breast cancer treatment? | Q34218149 | ||
| Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers | Q34579373 | ||
| Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer | Q34601123 | ||
| Adjuvant chemotherapy in older women with early-stage breast cancer | Q34858284 | ||
| The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer | Q67332740 | ||
| Phase I trial of escalating doses of cisplatin in hypertonic saline | Q68189739 | ||
| Cisplatin in the treatment of metastatic breast carcinoma: A prospective randomized trial of two dosage schedules | Q70236730 | ||
| A phase II study of cis-diamminedichloroplatinum II for advanced breast cancer. Two dose schedules | Q70510924 | ||
| CAP (cyclophosphamide, adriamycin, cisplatinum) in the treatment of advanced breast cancer | Q70815222 | ||
| Phase II clinical trial of cis-dichlorodiammine platinum (cis-DDP) for antitumorigenic activity in previously untreated patients with metastatic breast cancer | Q71236719 | ||
| Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers | Q79758509 | ||
| Potential chemotherapy options in the triple negative subtype of breast cancer | Q80077016 | ||
| Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients | Q81688258 | ||
| Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342 | Q35633680 | ||
| Platinum-based chemotherapy in metastatic breast cancer: current status. | Q35650449 | ||
| The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers | Q35745252 | ||
| Phase II study of neoadjuvant paclitaxel and cisplatin for operable and locally advanced breast cancer: analysis of 126 patients | Q36694650 | ||
| Oestrogen receptor status, pathological complete response and prognosis in patients receiving neoadjuvant chemotherapy for early breast cancer | Q36695226 | ||
| Triple-negative high-risk breast cancer derives particular benefit from dose intensification of adjuvant chemotherapy: results of WSG AM-01 trial | Q37049920 | ||
| Adjuvant chemotherapy in oestrogen-receptor-poor breast cancer: patient-level meta-analysis of randomised trials | Q37051591 | ||
| Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial. | Q37155629 | ||
| What is triple-negative breast cancer? | Q37325246 | ||
| Weekly paclitaxel in the adjuvant treatment of breast cancer. | Q37346811 | ||
| BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells | Q37355031 | ||
| Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design | Q37418501 | ||
| Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy | Q37467199 | ||
| Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer. | Q40303976 | ||
| Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group | Q40510447 | ||
| BRCA1 functions as a differential modulator of chemotherapy-induced apoptosis | Q40626126 | ||
| Inhibition of BRCA1 leads to increased chemoresistance to microtubule-interfering agents, an effect that involves the JNK pathway | Q40773708 | ||
| Homology-directed dna repair, mitomycin-c resistance, and chromosome stability is restored with correction of a Brca1 mutation | Q40798697 | ||
| Phase II study of cis-dichlorodiammineplatinum(II) in advanced breast cancer | Q40887308 | ||
| BRCA1 up-regulation is associated with repair-mediated resistance to cis-diamminedichloroplatinum(II). | Q41056489 | ||
| Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer | Q42450903 | ||
| Breast cancer molecular subtypes respond differently to preoperative chemotherapy | Q42482998 | ||
| The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes | Q42511189 | ||
| A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer | Q43074624 | ||
| Estrogen receptors and responses to chemotherapy and hormonal therapy in advanced breast cancer | Q43517097 | ||
| Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. | Q44362100 | ||
| Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy | Q44423612 | ||
| The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. | Q44618276 | ||
| Cisplatin as first-line therapy for metastatic breast cancer | Q45036830 | ||
| Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment | Q45099316 | ||
| Response to neoadjuvant therapy and disease free survival in patients with triple-negative breast cancer. | Q46119049 | ||
| Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer. | Q46121546 | ||
| Platinum-based chemotherapy in triple-negative breast cancer. | Q46358330 | ||
| Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. | Q46493659 | ||
| Primary resistance to docetaxel-based chemotherapy in metastatic breast cancer patients correlates with a high frequency of BRCA1 mutations | Q46508970 | ||
| Dose-dense and/or metronomic schedules of specific chemotherapies consolidate the chemosensitivity of triple-negative breast cancer: a step toward reversing triple-negative paradox | Q46509413 | ||
| Adjuvant docetaxel for node-positive breast cancer | Q46522790 | ||
| Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. | Q46765380 | ||
| Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer | Q46771645 | ||
| Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. | Q46862276 | ||
| 'Triple negative' breast cancer: a new area for phase III breast cancer clinical trials | Q46918686 | ||
| Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. | Q46966638 | ||
| Clinico-pathological characteristics of BRCA1- and BRCA2-related breast cancer. | Q53409967 | ||
| HER2 and Response to Paclitaxel in Node-Positive Breast Cancer | Q57578418 | ||
| Randomized Trial of Dose-Dense Versus Conventionally Scheduled and Sequential Versus Concurrent Combination Chemotherapy as Postoperative Adjuvant Treatment of Node-Positive Primary Breast Cancer: First Report of Intergroup Trial C9741/Cancer and Leu | Q57578575 | ||
| The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin | Q64388522 | ||
| P433 | issue | 1 | |
| P921 | main subject | breast cancer | Q128581 |
| triple-negative breast cancer | Q7843332 | ||
| chemotherapy | Q974135 | ||
| P304 | page(s) | 53-61 | |
| P577 | publication date | 2010-01-01 | |
| P1433 | published in | The Cancer Journal | Q2589130 |
| P1476 | title | Triple-negative breast cancer: role of specific chemotherapy agents | |
| P478 | volume | 16 |
| Q64912613 | (-)-Oleocanthal Prevents Breast Cancer Locoregional Recurrence After Primary Tumor Surgical Excision and Neoadjuvant Targeted Therapy in Orthotopic Nude Mouse Models. |
| Q47115127 | A Cell-Line-Specific Atlas of PARP-Mediated Protein Asp/Glu-ADP-Ribosylation in Breast Cancer |
| Q36432567 | A DNA repair BRCA1 estrogen receptor and targeted therapy in breast cancer |
| Q38432397 | A microRNA signature associated with pathological complete response to novel neoadjuvant therapy regimen in triple-negative breast cancer |
| Q94671596 | A novel prognostic two-gene signature for triple negative breast cancer |
| Q37024369 | A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protoc |
| Q55405558 | A randomized and open-label phase II trial reports the efficacy of neoadjuvant lobaplatin in breast cancer. |
| Q47151712 | APC loss in breast cancer leads to doxorubicin resistance via STAT3 activation. |
| Q35655334 | APC selectively mediates response to chemotherapeutic agents in breast cancer |
| Q41636352 | Adaptive Reprogramming of De Novo Pyrimidine Synthesis Is a Metabolic Vulnerability in Triple-Negative Breast Cancer |
| Q37990824 | Adjuvant therapy in stage I carcinoma of the breast: the influence of multigene analyses and molecular phenotyping |
| Q38023589 | Adjuvant therapy in stage I carcinoma of the breast: the influence of multigene analyses and molecular phenotyping. |
| Q60937807 | Apoptosis Induction via ATM Phosphorylation, Cell Cycle Arrest, and ER Stress by Goniothalamin and Chemodrugs Combined Effects on Breast Cancer-Derived MDA-MB-231 Cells |
| Q93059408 | Apoptotic Resistance of Metastatic Tumor Cells in Triple Negative Breast Cancer: Roles of Death Receptor-5 |
| Q33829321 | Binding of galectin-1 to integrin β1 potentiates drug resistance by promoting survivin expression in breast cancer cells |
| Q90284585 | Both BRCA1-wild type and -mutant triple-negative breast cancers show sensitivity to the NAE inhibitor MLN4924 which is enhanced upon MLN4924 and cisplatin combination treatment |
| Q91099817 | Brain metastases |
| Q38386346 | Breast cancer under age 40: a different approach |
| Q98158906 | CHARACTERISTICS AND PROGNOSIS OF TRIPLE-NEGATIVE BREAST CANCER PATIENTS: A CROATIAN SINGLE INstitution RETROSPECTIVE COHORT STUDY |
| Q33867131 | Cancer stem cells: a novel paradigm for cancer prevention and treatment |
| Q37214592 | Cellular uptake mechanism and comparative evaluation of antineoplastic effects of paclitaxel-cholesterol lipid emulsion on triple-negative and non-triple-negative breast cancer cell lines |
| Q36057728 | Chemotherapy-induced peripheral neurotoxicity and ototoxicity: new paradigms for translational genomics |
| Q38694338 | Codelivery of Anti-cancer Agents via Double-walled Polymeric Microparticles/ Injectable Hydrogel: A Promising Approach for Treatment of Triple Negative Breast Cancer |
| Q33919246 | Curcumin: the spicy modulator of breast carcinogenesis. |
| Q33579896 | DNA methyltransferases: a novel target for prevention and therapy |
| Q91992110 | Delivery of Anti-miRNA for Triple-Negative Breast Cancer Therapy Using RNA Nanoparticles Targeting Stem Cell Marker CD133 |
| Q33601365 | Docetaxel-Loaded PLGA Nanoparticles Improve Efficacy in Taxane-Resistant Triple-Negative Breast Cancer. |
| Q58104057 | Dynamin impacts homology-directed repair and breast cancer response to chemotherapy |
| Q92133957 | Efficacy and safety profiles of programmed cell death-1/programmed cell death ligand-1 inhibitors in the treatment of triple-negative breast cancer: A comprehensive systematic review |
| Q37511632 | Epigenetic silencing of ARRDC3 expression in basal-like breast cancer cells |
| Q91843376 | Establishment of chemosensitivity tests in triple-negative and BRCA-mutated breast cancer patient-derived xenograft models |
| Q89617913 | Fangjihuangqi Decoction inhibits MDA-MB-231 cell invasion in vitro and decreases tumor growth and metastasis in triple-negative breast cancer xenografts tumor zebrafish model |
| Q47437905 | Genome-wide analysis of the three-way interplay among gene expression, estrogen receptor expression and chemotherapeutic sensitivity in breast cancer |
| Q29248638 | Genome-wide profiles of methylation, microRNAs, and gene expression in chemoresistant breast cancer |
| Q37262447 | Gold Nanoantenna-Mediated Photothermal Drug Delivery from Thermosensitive Liposomes in Breast Cancer |
| Q33933721 | Healthcare costs in women with metastatic breast cancer receiving chemotherapy as their principal treatment modality |
| Q47125869 | High PD-L1 Expression Is Closely Associated With Tumor-Infiltrating Lymphocytes and Leads to Good Clinical Outcomes in Chinese Triple Negative Breast Cancer Patients |
| Q50003353 | Identification of Staphylococcus aureus α-hemolysin as a protein drug that is secreted by anticancer bacteria and rapidly kills cancer cells |
| Q58702853 | Identification of tRNA-derived small noncoding RNAs as potential biomarkers for prediction of recurrence in triple-negative breast cancer |
| Q64105917 | Impact of age on pathological complete response and locoregional recurrence in locally advanced breast cancer after neoadjuvant chemotherapy |
| Q41531931 | Impressive Response to Concomitant Platinum-based Chemotherapy and Yttrium-90 in a Patient with Heavily Pretreated Triple-negative Breast Cancer Widely Metastasized to the Liver |
| Q64951827 | In silico simulation of a clinical trial with anti-CTLA-4 and anti-PD-L1 immunotherapies in metastatic breast cancer using a systems pharmacology model. |
| Q38837835 | Inorganic Phosphate Prevents Erk1/2 and Stat3 Activation and Improves Sensitivity to Doxorubicin of MDA-MB-231 Breast Cancer Cells. |
| Q37574955 | Investigating the discernible and distinct effects of platinum-based chemotherapy regimens for metastatic triple-negative breast cancer on time to progression |
| Q44273702 | Investigation of molecular alterations of AKT-3 in triple-negative breast cancer |
| Q91972947 | Isoliquiritigenin Derivative Regulates miR-374a/BAX Axis to Suppress Triple-Negative Breast Cancer Tumorigenesis and Development |
| Q36551346 | Long-Term Complete Remission with nab-Paclitaxel, Bevacizumab, and Gemcitabine Combination Therapy in a Patient with Triple-Negative Metastatic Breast Cancer |
| Q38148063 | Long-term treatment after preoperative high-dose chemotherapy in a lactating breast cancer patient |
| Q38733113 | MENA Confers Resistance to Paclitaxel in Triple-Negative Breast Cancer |
| Q50455931 | MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib |
| Q35155460 | Management options in triple-negative breast cancer |
| Q54537693 | Methylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients. |
| Q48263230 | MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1. |
| Q34562257 | Minireview: Basal-like breast cancer: from molecular profiles to targeted therapies |
| Q38677841 | Neoadjuvant Chemotherapy In Triple-Negative Breast Cancer: A Multicentric Retrospective Observational Study In Real-Life Setting. |
| Q40774797 | Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study |
| Q54979733 | Neuropilin-1 promotes the oncogenic Tenascin-C/integrin β3 pathway and modulates chemoresistance in breast cancer cells. |
| Q90477297 | New substituted quinoxalines inhibit triple-negative breast cancer by specifically downregulating the c-MYC transcription |
| Q36956874 | Nodal expression in triple-negative breast cancer: Cellular effects of its inhibition following doxorubicin treatment |
| Q28388647 | Norcantharidin, derivative of cantharidin, for cancer stem cells |
| Q37426564 | Noscapine chemosensitization enhances docetaxel anticancer activity and nanocarrier uptake in triple negative breast cancer |
| Q33591623 | ONC201 activates ER stress to inhibit the growth of triple-negative breast cancer cells |
| Q48336503 | Oestrogen receptor negative early operable primary breast cancer in older women-Biological characteristics and long-term clinical outcome. |
| Q38259259 | PI3K/AKT/mTOR pathway inhibitors: the ideal combination partners for breast cancer therapies? |
| Q35990463 | Pathological complete response in younger and older breast cancer patients |
| Q64906560 | Piperlongumine Induces Apoptosis and Synergizes with Doxorubicin by Inhibiting the JAK2-STAT3 Pathway in Triple-Negative Breast Cancer. |
| Q37727996 | Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics |
| Q38155673 | Primary therapy in breast cancer: what have we learned from landmark trials? |
| Q90049397 | Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis |
| Q40296843 | Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome. |
| Q28235715 | Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation |
| Q86588472 | RETRACTED ARTICLE: Enhancement of doxorubicin efficacy through suppression of serine synthesis in triple-negative breast cancer |
| Q44292349 | RETRACTED: Inhibition of PKM2 sensitizes triple-negative breast cancer cells to doxorubicin |
| Q47126394 | Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer |
| Q28391395 | Reinventing diagnostics for personalized therapy in oncology |
| Q54349758 | Relationship between chemotherapy and prognosis in different subtypes of node-negative breast cancer. |
| Q43421701 | Risk and healthcare costs of chemotherapy-induced neutropenic complications in women with metastatic breast cancer |
| Q90010266 | Role of Muscarinic Acetylcholine Receptors in Breast Cancer: Design of Metronomic Chemotherapy |
| Q45967836 | Role of Taxanes in Triple-Negative Breast Cancer: A Study From Tertiary Cancer Center in South India. |
| Q39088864 | Stress-induced EGF receptor signaling through STAT3 and tumor progression in triple-negative breast cancer |
| Q41290532 | Structure-activity relationships and molecular docking studies of chromene and chromene based azo chromophores: A novel series of potent antimicrobial and anticancer agents |
| Q35128130 | Suberoyl bis-hydroxamic acid enhances cytotoxicity induced by proteasome inhibitors in breast cancer cells |
| Q46857381 | Suppression of the xCT-CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin |
| Q27853147 | TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer |
| Q40630370 | Tailoring combinatorial cancer therapies to target the origins of adaptive resistance |
| Q36157045 | Targeted nanoparticles for image-guided treatment of triple-negative breast cancer: clinical significance and technological advances |
| Q89500713 | Targeting PP2A inhibits the growth of triple-negative breast cancer cells |
| Q38823095 | Targeting cancer stem cells and signaling pathways by phytochemicals: Novel approach for breast cancer therapy |
| Q91989182 | Targeting immune pathways in breast cancer: review of the prognostic utility of TILs in early stage triple negative breast cancer (TNBC) |
| Q58702607 | The "Yin and Yang" of Natural Compounds in Anticancer Therapy of Triple-Negative Breast Cancers |
| Q37720246 | The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer |
| Q26798356 | The role of taxanes in triple-negative breast cancer: literature review |
| Q34302752 | The treatment and survival of patients with triple negative breast cancer in a London population |
| Q37414318 | Theranostic barcoded nanoparticles for personalized cancer medicine |
| Q34331406 | Treatment options for patients with triple-negative breast cancer |
| Q38007037 | Triple negative breast cancer: a brief review of its characteristics and treatment options |
| Q60914202 | Triptolide Decreases Cell Proliferation and Induces Cell Death in Triple Negative MDA-MB-231 Breast Cancer Cells |
| Q92705301 | Two Natural Alkaloids Synergistically Induce Apoptosis in Breast Cancer Cells by Inhibiting STAT3 Activation |
| Q36311616 | Update on triple-negative breast cancer: prognosis and management strategies |
| Q50053475 | Variation in guideline-concordant care for elderly patients with metastatic breast cancer in the United States |
| Q33576814 | microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers |
| Q36794562 | pH-responsive artemisinin dimer in lipid nanoparticles are effective against human breast cancer in a xenograft model |
| Q35029494 | α-TEA cooperates with chemotherapeutic agents to induce apoptosis of p53 mutant, triple-negative human breast cancer cells via activating p73. |
Search more.